Dr. Rita Elena Tamargo, PSYD., MA. Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 5 Calle Nairn, Condado, PR 00907 Phone: 939-940-5416 |
Mrs. Teresa Marie Colon, MA Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 1452 Ave Ashford, Ada Lligia 408, Condado, PR 00907 Phone: 787-649-7212 |
News Archive
The Muscular Dystrophy Association today celebrated news of the U.S. Food and Drug Administration's decision to grant approval for nusinersen (brand name Spinraza), the first disease-modifying drug to treat the most common genetic cause of death in infants.
Pharmasset, Inc. announced today that dosing has begun in Part 2 of a Phase 1 study. This is the first clinical study combining a purine (PSI-938) and a pyrimidine (PSI-7977) nucleotide analog for HCV, and is designed to evaluate once daily doses of PSI-7977 and PSI-938 in patients with HCV who have not been treated previously.
An interdisciplinary team of researchers from the University of Texas Medical Branch at Galveston and the University of Houston has found a new way to influence the vital serotonin signaling system - possibly leading to more effective medications with fewer side effects.
URL Pharma, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Colcrys(TM) (colchicine, USP) for the prophylaxis (prevention) of gout flares. Colcrys was first approved by the FDA on July 30, 2009 for the treatment of acute gout flares when taken at the first sign of a flare.
› Verified 9 days ago